Who makes routine dose tacrolimus and less myfortic?

routine dose tacrolimus and less myfortic is developed by Asan Medical Center.

What development phase is routine dose tacrolimus and less myfortic in?

routine dose tacrolimus and less myfortic is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

routine dose tacrolimus and less myfortic

Asan Medical Center · FDA-approved active Small molecule Quality 0/100

The combination of routine dose tacrolimus and less Myfortic is a marketed immunosuppressive regimen primarily used in transplant medicine, positioned to reduce the side effects associated with higher doses of Myfortic while maintaining efficacy. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity and revenue stability. The primary risk is the lack of robust clinical trial data to support broader adoption, potentially limiting market expansion.

At a glance

Generic name	routine dose tacrolimus and less myfortic
Sponsor	Asan Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

routine dose tacrolimus and less myfortic CI brief — competitive landscape report
routine dose tacrolimus and less myfortic updates RSS · CI watch RSS
Asan Medical Center portfolio CI